Modulation of Agonist Efficacy at the Human A3 Adenosine Receptor by LUF6000
Author Information
Author(s): Gao Zhan-Guo, Ye Kai, Göblyös Anikó, IJzerman Adriaan P, Jacobson Kenneth A
Primary Institution: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
Hypothesis
How does LUF6000 modulate the efficacy of agonists at the human A3 adenosine receptor?
Conclusion
LUF6000 enhances the maximum effect of low-efficacy agonists at the A3 adenosine receptor more than that of high-efficacy agonists.
Supporting Evidence
- LUF6000 enhanced the Emax of Cl-IB-MECA and other low-efficacy agonists significantly.
- LUF6000 converted the nucleoside antagonist MRS542 into an agonist.
- Mathematical modeling supported the observed effects of LUF6000 on agonist efficacy.
Takeaway
LUF6000 helps some medicines work better by making weak ones stronger, but it doesn't help the strong ones much.
Methodology
The study used a [35S]GTPγS binding assay to measure the effects of LUF6000 on various agonists at the A3 adenosine receptor expressed in CHO cells.
Limitations
The study primarily focused on a specific receptor type and may not generalize to other receptors or conditions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website